<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1362</td>
<td>OPINION REVIEW</td>
<td>How far along are we in revealing the connection between metformin and colorectal cancer? Berkovic MC, Mikulic D, Bilic-Curcic I, Mrzljak A</td>
</tr>
<tr>
<td>1369</td>
<td>REVIEW</td>
<td>Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B Goh ZY, Ren EC, Ko HL</td>
</tr>
<tr>
<td>1392</td>
<td>MINIREVIEWS</td>
<td>Artificial intelligence-assisted endoscopic detection of esophageal neoplasia in early stage: The next step? Liu Y</td>
</tr>
<tr>
<td>1419</td>
<td>Basic Study</td>
<td>Lipotoxic hepatocyte-derived exosomal miR-1297 promotes hepatic stellate cell activation through the PTEN signaling pathway in metabolic-associated fatty liver disease Luo X, Luo SZ, Xu ZX, Zhou C, Li ZH, Zhou XY, Xu MY</td>
</tr>
<tr>
<td>1435</td>
<td>Retrospective Cohort Study</td>
<td>Cyanidin 3-glucoside modulated cell cycle progression in liver precancerous lesion, in vivo study Matboli M, Hasanin AH, Hussein R, El-Nakeep S, Habib EK, Ellackany R, Saleh LA</td>
</tr>
<tr>
<td>1451</td>
<td>Retrospective Cohort Study</td>
<td>Stapled transperineal repair for low- and mid-level rectovaginal fistulas: A 5-year experience and comparison with sutured repair Zhou Q, Liu ZM, Chen HX, Ren DL, Lin HC</td>
</tr>
<tr>
<td>1465</td>
<td>Retrospective Study</td>
<td>Impact of preoperative antibiotics and other variables on integrated microbiome-host transcriptomic data generated from colorectal cancer resections Malik SA, Zhu C, Li J, LaCombe JF, Denaya PI, Kravets I, Miller JD, Yang J, Kramer M, McCombie WR, Robertson CE, Frank DN, Li E</td>
</tr>
</tbody>
</table>
Observational Study

1497  Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss

Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L

META-ANALYSIS

1507  T-tube vs no T-tube for biliary tract reconstruction in adult orthotopic liver transplantation: An updated systematic review and meta-analysis

ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Takuya Watanabe, MD, PhD, Director, Department of Internal Medicine and Gastroenterology, Watanabe Internal Medicine Aoyama Clinic, Aoyama 1-2-21, Nishi-ku, Niigata 950-2002, Japan, nabetaku@dia-net.ne.jp

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for WJG as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2019 is 7.1 and Scopus CiteScore rank 2019: Gastroenterology is 17/137.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ji-Hong Liu; Production Department Director: Yun-Xiaojian Wu; Editorial Office Director: Ze-Mao Gong.
How far along are we in revealing the connection between metformin and colorectal cancer?

Maja Cigrovski Berkovic, Danko Mikulic, Ines Bilic-Curcic, Anna Mrzljak

ORCID number: Maja Cigrovski Berkovic 0000-0003-0750-9785; Danko Mikulic 0000-0001-8103-6045; Ines Bilic-Curcic 0000-0002-8861-5987; Anna Mrzljak 0000-0001-6270-2305.

Author contributions: Cigrovski Berkovic M made contributions to the conception and design of the study and drafted and revised the manuscript critically; Mikulic D, Bilic-Curcic I, and Mrzljak A were involved in collecting data and drafting and writing the manuscript; all authors read and approved the final manuscript.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Abstract

Colorectal cancer (CRC) is among the most prevalent cancers worldwide, and its prevention and reduction of incidence is imperative. The presence of diabetes has been associated with a 30% increased risk of CRC, likely through the mechanism of hyperinsulinemia, which promotes tumorigenesis via the insulin receptor in the epithelium or by insulin-like growth factor pathways, inflammation, or adipokines, inducing cancer cell proliferation and cancer spread. Metformin, the first-line agent in treating type 2 diabetes, has a chemopreventive role in CRC development. Additionally, preclinical studies suggest synergistic effects of metformin with oxaliplatin in inhibiting in vitro models of colon cancer. Although preclinical studies on the post diagnostic use of metformin were promising and suggested its synergistic effects with chemotherapy, the data on the possible effects of metformin after surgery and other CRC treatment in the clinical setting are less conclusive, and randomized controlled trials are still lacking.

Key Words: Metformin; Type 2 diabetes mellitus; Colorectal cancer; Chemoprevention; Recurrence-free survival; Surgery

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
INTRODUCTION

Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, irrespective of gender. Factors contributing to the risk of development of CRC include lifestyle, genetics, and chronic diseases such as diabetes mellitus and obesity[1-3]. Although patient survival has increased over the years due to more effective treatments, there is still a problem with adverse effects and therapy costs. The prevention and reduction of CRC incidence is imperative. Several agents with chemopreventive effects have emerged. Cyclooxygenase-2 inhibitors offered the most promising results in CRC prevention, but their use was associated with elevated cardiovascular risk. Considering that CRC patients often have diabetes mellitus and obesity, which also confers cardiovascular risk, novel targets for CRC chemoprevention are needed. Accumulating data indicates that metformin, the first-line treatment for type 2 diabetes mellitus, may be a candidate chemoprevention agent for cancer, including CRC.

METFORMIN-CLINICAL USE AND MODE OF ACTION

Metformin is one of the oldest oral antidiabetic agents used to treat type 2 diabetes mellitus alone or in combination with other oral or injectable agents. It lowers blood glucose levels by reducing hepatic glucose production, stimulating glucose uptake by peripheral tissues (muscle and fat), and lowering intestinal glucose absorption[4-5]. The presence of diabetes has been associated with a 30% increased risk of CRC. This potentially occurs through the mechanism of hyperinsulinemia accompanying insulin resistance, which promotes tumorigenesis on the insulin receptor in the epithelium or by influencing insulin-like growth factor pathways, inflammation, or adipokines inducing cancer cell proliferation and metastasis[6,7]. Therefore, metformin might provide preventive effects by reducing insulin resistance and lowering hyperinsulinemia[8] (Figure 1). Additionally, the use of metformin in various cancer models provided anticarcinogenic action by inhibiting angiogenesis or through antimalbio and radio-chemosensitizer effects[8]. This is mediated by the synergistic regulation of metformin on adenosine monophosphate-activated protein kinase (AMPK), glycogen synthase kinase-3β, and proliferator-activated receptor-γ as observed in the case of pancreatic cancer[9].

The mechanistic target of rapamycin (mTOR) pathway, with complex multiple feedback loops, plays a central role in coordinating cell growth and proliferation in CRC carcinogenesis. Different mTOR inhibitors have been extensively studied for preventing and/or treating CRC, but no single agent has shown a significant therapeutic efficacy towards CRC potentially because many of the genetic pathways involved in CRC development lie upstream of mTOR and elicit the oncogenic effect through the mTOR signaling pathway[10]. According to the contemporary understanding, the mTOR pathway is continuously activated by various hormones, inflammation, and energy-related factors such as glucose, insulin, and insulin-like growth factor 1. The hypothesis to combine inhibition of these pathways seems promising in providing more effective tumor suppression[10]. Metformin inhibits mitochondrial mammalian respiratory chain complex I followed by activation of liver kinase B1 and downstream target AMPK that results in an inhibition of mTOR activity[11,12]. Metformin also exerts its metabolic effects by improving insulin resistance, hyperinsulinemia, and glycemia. Metformin has apoptotic effects on cancer

Citation: Berkovic MC, Mikulic D, Bilic-Curcic I, Mrzljak A. How far along are we in revealing the connection between metformin and colorectal cancer? World J Gastroenterol 2021; 27(14): 1362-1368
URL: https://www.wjgnet.com/1007-9327/full/v27/i14/1362.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i14.1362
stem cells and potentially has a synergistic effect with other chemotherapeutics\cite{15,16}.

Animal and in vitro studies indicate that the role of metformin as an antiproliferative agent on CRC cells is through the activation of AMPK\cite{17,18}. One of the first reports on anticancer effect of metformin in a CRC cell model showed the concentration and time-dependent effects on AMPK activation and the reduction of cancer cell proliferation\cite{19}. Other research provided further evidence of the apoptotic effects of metformin by modulating oxidative stress and nuclear factor-κB inflammatory responses\cite{20-22}. In the in vitro models, metformin was used either alone or in combination with other agents, primarily fluorouracil (commonly referred to as 5-FU)\cite{20,23-25}, which is similar to its use in clinics.

**CHEMOPREVENTIVE EFFECTS OF METFORMIN IN CRC TREATMENT**

Previous studies have indicated that metformin may decrease the risk of development of colorectal carcinoma\cite{26,27}. Observational data indicates lower tumor incidence in diabetic patients taking metformin, and results from interventional studies show a reduction in the incidence of colorectal adenomas in patients without diabetes taking low-dose metformin\cite{28-30}. Specifically, in a phase 3 randomized trial, a 1-year treatment with low-dose metformin reduced the number and prevalence of premalignant colorectal lesions, such as polyps and adenomas, in patients without diabetes post polypectomy\cite{30}. A recently published retrospective cohort study including 47351 people found an inverse association between long-term (> 5 years) exposure to metformin in diabetic patients and the risk of CRC\cite{31}, suggesting its chemopreventive potential. This finding was substantiated with the meta-analysis results of 58 studies showing that metformin usage significantly reduced the incidence of colorectal adenoma and CRC, improving overall and CRC-specific survival rates\cite{32}.

On the other hand, data on the role metformin plays in CRC carcinogenesis in nondiabetic patients are not extensive. According to the randomized placebo-controlled trial results, metformin has the chemopreventive potential in nondiabetic patients with a high risk for CRC development\cite{33}. Although metformin therapy was usually well tolerated by patients with different cancers and side effects did not differ from those seen in diabetic patients (dose-related gastrointestinal adverse effects, rarely lactic acidosis, and vitamin B12 deficiency), more data are needed on the optimal dose, schedule, route of administration, treatment duration, and combinations with other chemotherapeutic agents for CRC patients (especially nondiabetic patients) to be able to minimize the potential side effects\cite{34-36}.
METFORMIN AND SURVIVAL OF PATIENTS UNDERGOING TREATMENT FOR CRC

While there is substantial evidence that metformin may have a chemopreventive role in CRC development, the data on the possible effects of metformin after surgery and other CRC treatments are much less conclusive.

Lee et al. first observed a protective effect of metformin after CRC diagnosis in a single institution cohort of 595 patients. Metformin use showed a lower risk of overall mortality [hazard ratio (HR) = 0.66; 95% confidence interval (CI): 0.476-0.923] and CRC-specific mortality (HR = 0.66; 95% CI: 0.45-0.975) in patients with diabetes. However, this analysis suffered from immortal time bias, which may have influenced the results. Fransgaard et al. examined the association between metformin and overall survival after resection for CRC in patients from the national Danish CRC database. They found better overall survival of patients treated with metformin compared to patients treated with insulin. However, cancer-specific mortality was not differentiated from diabetes-specific mortality, and it is not clear what their respective roles were in all-cause mortality. Therefore, it is impossible to ascertain whether better overall survival in the metformin-treated group can be attributed to metformin or the antitumor effects of other factors. Interestingly, in a recent paper, the same group found no association between metformin use and recurrence-free survival or disease-free survival in patients with surgically treated CRC. The findings of a large population-based analysis from the United Kingdom also do not support a protective association between post-diagnostic metformin use and survival in a cohort of CRC patients with type 2 diabetes mellitus.

Several meta-analyses have been published on the topic, and most of them have reported a reduction in CRC-specific mortality with metformin use compared with nonuse in CRC patients. However, the studies included in these meta-analyses are very heterogeneous regarding their design and inclusion criteria (e.g., analyzing patients with different CRC stages). Also, information is often not available on the types of surgeries and administered chemotherapy in the included studies.

Evidence exists that metformin in combination with adjuvant therapy may be associated with a better prognosis in CRC patients treated with metformin post-surgery. In preclinical studies, metformin has shown synergistic effects with oxaliplatin in inhibiting in vitro models of colon cancer. Based on such evidence, it was hypothesized that metformin combined with adjuvant chemotherapy might be associated with a better prognosis in patients with resected CRC. This was not confirmed in the setting of a randomized study in patients with resected high-risk stage II or stage III CRC who received FOLFOX-4/XELOX adjuvant therapy. Another study exploring the impact of metformin on overall survival and recurrence-free survival in a homogeneous group of stage III CRC patients receiving FOLFOX adjuvant therapy failed to find a significant association.

These findings stand in contrast to the findings of studies that found an association between metformin use and improved outcomes. However, these were the studies that considered patients with stages I-IV treated with different chemotherapy regimens, including both patients with low stages without adjuvant chemotherapy and patients with advanced stages who received multiple chemotherapeutics. Therefore, the effect of metformin on overall survival and recurrence-free survival in patients with CRC receiving chemotherapy after resection remains uncertain. Extensive prospective studies that include homogenous patient populations, ideally within randomized trials, with longer follow-up would provide more evidence on the possible association of metformin use and improved survival of patients after CRC treatment.

CONCLUSION

Mounting evidence suggests a chemopreventive role of metformin on CRC development, but the data on its role in diagnosed CRC in adjunct to surgery and chemotherapy are still inconclusive. Additional evidence from prospective, randomized controlled trials are required.

REFERENCES

Cigrovski Berkovic M et al. Connection between metformin and CRC

1 30620402 DOI: 10.3322/caac.21551
7 Godstand IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond) 2009; 118: 315-332 [PMID: 19922415 DOI: 10.1042/CS20090399]
24 Feng YH, Wu CL, Shiu AL, Lee JC, Chang JG, Lu PJ, Tung CL, Feng LY, Huang WT, Tsao CJ. MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-


Cigrovski Berkovic M et al. Connection between metformin and CRC

2017; 8: 26448-26459 [PMID: 28103573 DOI: 10.18632/oncotarget.14688]


